Roche

Johns Hopkins Study Exposes Orphan Drug Act Gaming - Seven of Top 10 Drugs Exploiting Tax Breaks for Rare Diseases

2015-11-19 00:00:00 +0000 UTC | Importance: 9/10

Johns Hopkins researchers published findings demonstrating that pharmaceutical companies were systematically gaming the 1983 Orphan Drug Act by obtaining orphan drug designations—intended for treatments of rare diseases affecting fewer than 200,000 Americans—for blockbuster drugs generating billions …

Johns Hopkins University FDA AbbVie Roche Johnson & Johnson +4 more pharmaceutical-industry regulatory-capture tax-avoidance drug-pricing healthcare +2 more

FDA Arthritis Drug Reviewer Jeffrey Siegel Joins Genentech After Approving Company Tocilizumab

2010-12-15 00:00:00 +0000 UTC | Importance: 7/10

Jeffrey Siegel, an FDA staff member specializing in arthritis drug reviews, oversaw the 2010 approval of Genentech tocilizumab (Actemra) for arthritis treatment. Within months of the approval, Siegel left the FDA to join Genentech and its parent company Roche as director of the division that …

Jeffrey Siegel FDA Genentech Roche Actemra regulatory-capture pharmaceutical-industry fda revolving-door drug-approval